Marta Gutiérrez-Valencia1, Pablo Aldaz Herce2, Esther Lacalle-Fabo3, Beatriz Contreras Escámez4, Bernardo Cedeno-Veloz5, Nicolás Martínez-Velilla4. 1. Servicio de Farmacia, Navarrabiomed, Universidad Pública de Navarra (UPNA), Complejo Hospitalario de Navarra (CHN), IdiSNA, Pamplona, Navarra, España. Electronic address: marta.guva@gmail.com. 2. Centro de Salud de San Juan, Pamplona, Navarra, España. 3. Servicio de Farmacia, Complejo Hospitalario de Navarra, Pamplona, Navarra, España. 4. Servicio de Geriatría, Navarrabiomed, Universidad Pública de Navarra (UPNA), Complejo Hospitalario de Navarra (CHN), IdiSNA, Pamplona, Navarra, España. 5. Servicio de Geriatría, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.
Abstract
BACKGROUND AND OBJECTIVE: to estimate the prevalence of polypharmacy and hyperpolypharmacy in non-institutionalised older adults in Spain and assess the associated factors. MATERIAL AND METHODS: a cross-sectional study based on data from the National Health Survey of Spain 2017, with participants aged 65 and over. The prevalence of polypharmacy (≥5 medications) and hyperpolypharmacy (≥10) were estimated, as well as the association with several factors through multivariate logistic regression. A sensitivity analysis was carried out considering the possible consumption of more than one drug for the same indication (polytherapy). RESULTS: 7023 participants were included, with a mean age of 76.0 (SD 7.6), 59.4% female and average consumption of 3.3 (SD 2.2) drugs per person. The prevalence of polypharmacy was 27.3% (95% CI 26.2-28.3) and of hyperpolypharmacy 0.9% (95% CI 0.7-1.1). The sensitivity analysis showed that the prevalence could be at least 37.5% and the average 3.9 (SD 2.5) when considering polytherapy. The factors most associated with polypharmacy were the number of chronic diseases, degree of dependence for the basic activities of daily living, self-perceived health or contacts with the health system; and negatively, sensory deficits and incontinence. CONCLUSIONS: the prevalence of polypharmacy in the elderly in primary care continues to increase and could be widely underestimated. In addition to multimorbidity, factors such as functional capacity or geriatric syndromes, fundamental in elderly people, modulate the habits of consumption and prescription of drugs in this population.
BACKGROUND AND OBJECTIVE: to estimate the prevalence of polypharmacy and hyperpolypharmacy in non-institutionalised older adults in Spain and assess the associated factors. MATERIAL AND METHODS: a cross-sectional study based on data from the National Health Survey of Spain 2017, with participants aged 65 and over. The prevalence of polypharmacy (≥5 medications) and hyperpolypharmacy (≥10) were estimated, as well as the association with several factors through multivariate logistic regression. A sensitivity analysis was carried out considering the possible consumption of more than one drug for the same indication (polytherapy). RESULTS: 7023 participants were included, with a mean age of 76.0 (SD 7.6), 59.4% female and average consumption of 3.3 (SD 2.2) drugs per person. The prevalence of polypharmacy was 27.3% (95% CI 26.2-28.3) and of hyperpolypharmacy 0.9% (95% CI 0.7-1.1). The sensitivity analysis showed that the prevalence could be at least 37.5% and the average 3.9 (SD 2.5) when considering polytherapy. The factors most associated with polypharmacy were the number of chronic diseases, degree of dependence for the basic activities of daily living, self-perceived health or contacts with the health system; and negatively, sensory deficits and incontinence. CONCLUSIONS: the prevalence of polypharmacy in the elderly in primary care continues to increase and could be widely underestimated. In addition to multimorbidity, factors such as functional capacity or geriatric syndromes, fundamental in elderly people, modulate the habits of consumption and prescription of drugs in this population.
Keywords:
Adultos mayores; Atención primaria; Encuesta Nacional de Salud; National Health Survey; Older adults; Polifarmacia; Polypharmacy; Primary care
Authors: Marisa Baré; Susana Herranz; Rosa Jordana; Maria Queralt Gorgas; Sara Ortonobes; Daniel Sevilla; Elisabet De Jaime; Olatz Ibarra; Candelaria Martín Journal: BMJ Open Date: 2020-01-26 Impact factor: 2.692
Authors: María Fernández-Prada; Paula García-González; Alejandro García-Morán; Inés Ruiz-Álvarez; Covadonga Ramas-Diez; Carmen Calvo-Rodríguez Journal: Med Clin (Engl Ed) Date: 2021-08-09
Authors: Carol Rovira; Pilar Modamio; Joaquim Pascual; Joan Armengol; Cristian Ayala; Joan Gallego; Eduardo L Mariño; Anna Ramirez Journal: BMJ Open Date: 2022-02-09 Impact factor: 2.692
Authors: Marta Morales-Puerto; María Ruiz-Díaz; Marta Aranda-Gallardo; José Miguel Morales-Asencio; Purificación Alcalá-Gutiérrez; José Antonio Rodríguez-Montalvo; Álvaro León-Campos; Silvia García-Mayor; José Carlos Canca-Sánchez Journal: Int J Environ Res Public Health Date: 2022-07-14 Impact factor: 4.614
Authors: Felipe Mozo-Alonso; José P Novalbos-Ruiz; Juan C Duran-Alonso; Amelia Rodríguez-Martin Journal: Nutrients Date: 2021-05-06 Impact factor: 5.717